Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients

UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation

Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.

Listen to the Contagion Live interview online.

Learn more about the research involving Dr. Becker and Dr. Hite.

Related Stories

Debug Query for this